Revvity launches easy-to-use molecular diagnostics workflow for newborn screening

US-based Revvity, Inc. has announced the launch of its EONIS™ Q system, a CE-IVD declared platform enabling laboratories in countries that accept the CE marking to adopt molecular testing for spinal muscular atrophy (SMA) and severe combined immunodeficiency (SCID) in newborns.

For both inherited conditions, immediate detection is critical to advancing a positive outcome. For SMA, disease modifying therapies exist to stop progression of disease, and for SCID, immunoglobulin treatments combined with stem cell therapies can potentially cure a child, if intervention comes in time. However, to date, molecular testing for these and other congenital disorders is relatively low, due in part to cost restrictions and the technical expertise required to perform and interpret these tests.

The EONIS Q system simplifies and streamlines molecular testing for SMA and SCID with an innovative workflow, inclusive of the EONIS™ Q96 instrument, the EONIS™ SCID-SMA kit and dedicated EONIS™ EASI™ software.

The European Alliance for Newborn Screening in Spinal Muscular Atrophy (SMA), an advocacy group established by SMA Europe, mandates that by 2025, all newborns in Europe should be screened for SMA. The CE-IVD declaration of the EONIS Q system and other solutions like it advance progress toward achieving this goal.